CXCL6 can be helpful to the therapy of acute myeloid leukemia by improving arterial niche through the promotion of angiogenesis in human umbilical artery endothelial cells (HUAECs) and the reduction of apoptosis in MSCs and HUAEC.39 Furthermore, CXCL6 was upregulated by β-catenin.40 In rS-MSCs, GLS1 inhibition increased both β-catenin and CXCL6. This evidence concerns the gene GLS and acute myeloid leukemia.